Clinical trial
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003849 |
|---|---|
| Title | Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease |
| Official title | A Phase II Trial of C2B8 in Patients With Asymptomatic CD20+ B-Cell Follicular Small Cleaved Low-Grade Non-Hodgkin's Lymphoma or Relapsed CD20+ Hodgkin's Disease |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 39 |
| Start date | Jul 1, 1999 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2008 |
| First posted | May 3, 2004 |
| Last update posted | Jul 13, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: